CalciMedica (NASDAQ: CALC) — Company Overview, News & Financial Data
CalciMedica develops critical care therapies targeting acute inflammatory diseases, focusing on CRAC channel inhibitors.
CalciMedica
CalciMedica (NASDAQ:CALC) focuses on developing critical care therapies for patients with acute and life-threatening inflammatory diseases. This biopharmaceutical company is especially concentrated on leveraging its expertise in calcium release-activated calcium (CRAC) channel inhibitors to treat conditions such as acute pancreatitis and other diseases where CRAC channels play a key role. CalciMedica aims to revolutionize the way acute inflammatory conditions are treated by advancing its leading compound through clinical trials and ultimately to the market, making a significant impact on patient care. The company, solely listed on NASDAQ, embodies a mission to address the unmet medical needs in critical care with innovative, effective treatments.
Snapshot
Operations
Products and/or services of CalciMedica
- Auxora, a CRAC channel inhibitor for treating acute pancreatitis and COVID-19 pneumonia.
- Development of novel CRAC channel inhibitors for autoimmune diseases and neuroinflammatory disorders.
- Research on CRAC channel modulation to address acute lung injury.
- Exploration of therapies for critical care conditions, including sepsis and acute kidney injury.
- Investigation into applications of CRAC channel inhibitors for cardiac ischemia-reperfusion injury.
- Study of potential treatments for inflammatory bowel disease leveraging CRAC channel inhibition.
CalciMedica executive team
- A. Rachel LehenyCEO & Director
- Eric W. RobertsChief Business Officer & Vice Chairman of the Board
- Sudarshan HebbarChief Medical Officer
- Michael J. DunnPresident & COO
- Anjana RaoCo-Founder and Scientific Advisor
- Patrick HoganCo-Founder and Scientific Advisor
- Stefan FeskeCo-Founder and Scientific Advisor
- Kenneth A. StaudermanCo-Founder & Chief Scientific Officer
- Stephen B. BardinChief Financial Officer
- John M. DunnGeneral Counsel
Key financials
Reported results for CalciMedica , in USD.
- Market cap
- 9.6M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -6.7
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -23.1M | -29.6M | |
| 0 | -24.2M | -13.7M | |
| 0 | -38.1M | -34.4M | |
| 0 | -14.2M | -7.8M |